Global FFR as Prognosis in CAD Patients without Ischemia

Global fractional flow reserve (FFR) results from adding up FFR values of the three major coronary arteries. This figure represents the physiological atherosclerosis burden and can predict events at long term in patients without stenosis leading to ischemia.

Efecto a largo plazo de los balones liberadores con bajas dosis de paclitaxel

This recent study published in JAHA looked at major cardiovascular events (death, infarction and revascularization) at 5 years in 1122 patients with no significant stenosis (lesions with FFR > 0.8 n=275) or presenting at least one significant lesion successfully treated (post PCI FFR > 0.8 n=847).

FFR was measured in the three main coronary arteries and these values were added to stratify patients into global FFR tertiles (low ≤ 2.80, intermediate between 2.80 and 2.88, and high ≥ 2.88).

Patients in the lowest tertile presented more events at 5 years compared against the intermediate and high tertiles (27.5% vs 22.0% and 20.9%, respectively; p=0.040).

The highest events rate in the group with low global FFR was driven mainly by more revascularization (16.4% vs 11.3% and 11.8%, respectively; p=0.038).


Read also: Sapien 3 Performs Well in “Jobs” for Which It Is Not Designed.


For each additional 0.1 FFR there was a significant reduction in total events (HR 0.988; CI 95%, 0.977 to 0.998; p=0.023), infarctions (HR 0.982; CI 95%, 0.966 to 0.998; p=0.032) and revascularization (HR 0.985; CI 95%, 0.972 to 0.999; p=0.040).

This is one of the studies that most clearly shows the concept of FFR as a continuous variable with a large spectrum of greys, as opposed to a binary variable below or over 0.8. 

Conclusion

Global FFR (the added FFR values of the three main cardiac arteries) is capable of predicting events at 5 years even in patients without ischemia driven by stenosis. Global FFR can be interpreted as the burden of physiological atherosclerosis.

JAHA-120-017729free

Original Title: Global Fractional Flow Reserve Value Predicts 5-Year Outcomes in Patients With Coronary Atherosclerosis But Without Ischemia.

Reference: Stephane Fournier et al. J Am Heart Assoc. 2020;9:e017729.  DOI: 10.1161/JAHA.120.017729.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...

Radial Patency in Coronary Procedures: Is Heparin Enough or Should We Aim for Distal Transradial Access?

Transradial access is the preferred route in most coronary procedures due to its proven reduction in mortality compared to transfemoral access. However, one of...

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...